2009, Number 5
<< Back Next >>
Rev Mex Neuroci 2009; 10 (5)
The Miller Fisher Syndrome is a variety of the Guillain Barré Syndrome
Jiménez DR, Montante MA, Martínez MJ, Cruz FD, Ruíz FA, Ramírez HM, González MA, Fernández VJA
Language: Spanish
References: 9
Page: 367-370
PDF size: 111.55 Kb.
ABSTRACT
The Miller Fisher Syndrome is a variety of the Guillain Barré Syndrome. Its incidence is 1-2 per 100,000 habitants. It is
distinguished by the classic triad of oftalmoplegia, ataxia and areflexia. Generally, the patients present a good outcome. We
present a case studied in the Hospital Juarez de México, whose findings of the nerve conduction velocities and its treatment are
discussed.
REFERENCES
Van Doorn PA, Ruts L, Jacobs BC. Clinical features, pathogenesis, and treatment of Guillain-Barré syndrome. Lancet Neurol 2008; 7: 939-50.
Koga M. Antecedent infections in Fisher syndrome. Neurology 2005; 64: 1605-11.
Mori M, Kuwabara S, Fukutake T. Clinical features and prognosis of Miller Fisher Syndrome. Neurology 2001; 56: 1104-6.
Schimidt C, Jenni W, Weber J, Beer JH. Miller Fisher Syndrome, eine Variante des Guillain Barré Syndromes. Schweiz Med Forum 2003; 17(23): 407-9.
Mori M, Kuwabara S, Fukutake T, Yuki N, Hattori T. Clinical features and prognosis of Miller Fisher Syndrome. Neurology 2001; 56: 1104- 6.
Delanoe C, Sebire G, Landrieu P. Acute infammmatory demyelinating polyradiculopathy in children: Clinical and electrodiagnostic studies. Ann Neurol 1998; 44: 350-6.
Goran JA, MacLeod WN. Electrophysiologic studies in Miller Fisher Syndrome. Neurology 1984; 34: 685-8.
Mori M, Kuwabara S, Fukutake T, Hattori T. Plasmapheresis and Miller Fisher syndrome: analysis of 50 consecutive cases. J Neurol Neurosurg Psychiatry 2002; 72: 680.
Mori M, Kuwabara S, Fukutake T, Hattori T. Intravenous immunoglobulin Therapy for Miller Fisher syndrome. Neurology 2007; 68: 1144-6.
Full text